Literature DB >> 29883218

Influenza vaccine failure: failure to protect or failure to understand?

Gregory A Poland1.   

Abstract

INTRODUCTION: I propose that influenza vaccine failure be defined as receipt of a properly stored and administered vaccine with the subsequent development of documented influenza. Several mechanisms of vaccine failure occur and can - sometimes in combination - lead to what is termed 'vaccine failure.' Influenza vaccine failure occurs for many reasons, many of which are not true failures of the vaccine (e.g. improper vaccine storage/handling). AREAS COVERED: In this article, I discuss common causes of 'vaccine failure' that are appropriately or inappropriately attributed to vaccines. This includes host, pathogen, vaccine, and study design issues such as genetic restriction of immune response; failure to store, handle, and administer vaccine properly; issues of immunosuppression and immunosenescence; apparent but false vaccine failure; time-mediated failure; etc. EXPERT COMMENTARY: A proper framework and nosology for vaccine failure informs discussion about influenza vaccine efficacy and prevents misperceptions that in turn affect vaccine uptake. Influenza vaccine can only provide maximum protection to the extent that the circulating and vaccine strains closely match; the vaccine is stored, handled, and administered properly and within a time frame to result in development of protective levels of immunity; and it is administered to a host capable of immunologically responding with protective immune responses.

Entities:  

Keywords:  Vaccine storage; human; immunity; immunization programs; influenza; influenza vaccines; vaccination

Mesh:

Substances:

Year:  2018        PMID: 29883218      PMCID: PMC6330882          DOI: 10.1080/14760584.2018.1484284

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  34 in total

1.  A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season.

Authors:  Danuta M Skowronski; Naveed Z Janjua; Gaston De Serres; Anne-Luise Winter; James A Dickinson; Jennifer L Gardy; Jonathan Gubbay; Kevin Fonseca; Hugues Charest; Natasha S Crowcroft; Monique Douville Fradet; Nathalie Bastien; Yan Li; Mel Krajden; Suzana Sabaiduc; Martin Petric
Journal:  Clin Infect Dis       Date:  2012-04-26       Impact factor: 9.079

2.  Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates.

Authors:  Suzanne E Ohmit; Mark G Thompson; Joshua G Petrie; Swathi N Thaker; Michael L Jackson; Edward A Belongia; Richard K Zimmerman; Manjusha Gaglani; Lois Lamerato; Sarah M Spencer; Lisa Jackson; Jennifer K Meece; Mary Patricia Nowalk; Juhee Song; Marcus Zervos; Po-Yung Cheng; Charles R Rinaldo; Lydia Clipper; David K Shay; Pedro Piedra; Arnold S Monto
Journal:  Clin Infect Dis       Date:  2013-11-13       Impact factor: 9.079

3.  Reduced antibody responses to the pandemic (H1N1) 2009 vaccine after recent seasonal influenza vaccination.

Authors:  Yoon Seok Choi; Yun Hee Baek; Wonseok Kang; Seung Joo Nam; Jino Lee; Sooseong You; Dong-Yeop Chang; Jong-Chan Youn; Young Ki Choi; Eui-Cheol Shin
Journal:  Clin Vaccine Immunol       Date:  2011-08-03

4.  Low vaccine effectiveness against influenza A(H3N2) virus among elderly people in Denmark in 2012/13--a rapid epidemiological and virological assessment.

Authors:  K Bragstad; Hd Emborg; T K Fischer; M Voldstedlund; S Gubbels; B Andersen; K Molbak; Tg Krause
Journal:  Euro Surveill       Date:  2013-02-07

5.  Magnitude of potential biases in a simulated case-control study of the effectiveness of influenza vaccination.

Authors:  Jill M Ferdinands; David K Shay
Journal:  Clin Infect Dis       Date:  2011-11-17       Impact factor: 9.079

6.  Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains.

Authors:  John J Treanor; H Keipp Talbot; Suzanne E Ohmit; Laura A Coleman; Mark G Thompson; Po-Yung Cheng; Joshua G Petrie; Geraldine Lofthus; Jennifer K Meece; John V Williams; Lashondra Berman; Caroline Breese Hall; Arnold S Monto; Marie R Griffin; Edward Belongia; David K Shay
Journal:  Clin Infect Dis       Date:  2012-07-25       Impact factor: 9.079

7.  Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season.

Authors:  Edward A Belongia; Burney A Kieke; James G Donahue; Robert T Greenlee; Amanda Balish; Angie Foust; Stephen Lindstrom; David K Shay
Journal:  J Infect Dis       Date:  2009-01-15       Impact factor: 5.226

Review 8.  The personal touch: strategies toward personalized vaccines and predicting immune responses to them.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Nathaniel D Lambert; Iana H Haralambieva; Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2014-04-04       Impact factor: 5.217

Review 9.  The Xs and Y of immune responses to viral vaccines.

Authors:  Sabra L Klein; Anne Jedlicka; Andrew Pekosz
Journal:  Lancet Infect Dis       Date:  2010-05       Impact factor: 71.421

10.  Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains.

Authors:  Seth J Zost; Kaela Parkhouse; Megan E Gumina; Kangchon Kim; Sebastian Diaz Perez; Patrick C Wilson; John J Treanor; Andrea J Sant; Sarah Cobey; Scott E Hensley
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-06       Impact factor: 11.205

View more
  13 in total

1.  Live Influenza Vaccine Provides Early Protection against Homologous and Heterologous Influenza and May Prevent Post-Influenza Pneumococcal Infections in Mice.

Authors:  Yulia Desheva; Galina Leontieva; Tatiana Kramskaya; Igor Losev; Andrey Rekstin; Nadezhda Petkova; Polina Kudar; Alexander Suvorov
Journal:  Microorganisms       Date:  2022-06-02

2.  Vaccination of pregnant women against influenza: what is the optimal timing?

Authors:  Helena C Maltezou; Alexandros Rodolakis
Journal:  Hum Vaccin Immunother       Date:  2021-02-18       Impact factor: 3.452

3.  Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection.

Authors:  Andrea L Herrera; Christopher Van Hove; Mary Hanson; James B Dale; Rodney K Tweten; Victor C Huber; Diego Diel; Michael S Chaussee
Journal:  PLoS One       Date:  2020-06-23       Impact factor: 3.240

4.  Winter Is Coming! Clinical, Immunologic, and Practical Considerations for Vaccinating Patients With Inflammatory Bowel Disease During the Coronavirus Disease-2019 Pandemic.

Authors:  Gil Y Melmed; David T Rubin; Dermot P B McGovern
Journal:  Gastroenterology       Date:  2020-10-14       Impact factor: 22.682

Review 5.  Mumps Outbreaks in Vaccinated Populations-Is It Time to Re-assess the Clinical Efficacy of Vaccines?

Authors:  Anna R Connell; Jeff Connell; T Ronan Leahy; Jaythoon Hassan
Journal:  Front Immunol       Date:  2020-09-18       Impact factor: 7.561

Review 6.  Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines.

Authors:  Giuseppe Lofano; Corey P Mallett; Sylvie Bertholet; Derek T O'Hagan
Journal:  NPJ Vaccines       Date:  2020-09-18       Impact factor: 7.344

7.  Intranasal Nanoparticle Vaccination Elicits a Persistent, Polyfunctional CD4 T Cell Response in the Murine Lung Specific for a Highly Conserved Influenza Virus Antigen That Is Sufficient To Mediate Protection from Influenza Virus Challenge.

Authors:  Sean A Nelson; Thamotharampillai Dileepan; Amy Rasley; Marc K Jenkins; Nicholas O Fischer; Andrea J Sant
Journal:  J Virol       Date:  2021-07-26       Impact factor: 5.103

8.  Evidence That Blunted CD4 T-Cell Responses Underlie Deficient Protective Antibody Responses to Influenza Vaccines in Repeatedly Vaccinated Human Subjects.

Authors:  Katherine A Richards; Ian Shannon; John J Treanor; Hongmei Yang; Jennifer L Nayak; Andrea J Sant
Journal:  J Infect Dis       Date:  2020-06-29       Impact factor: 7.759

9.  Original Antigenic Sin and Respiratory Syncytial Virus Vaccines.

Authors:  Ralph A Tripp; Ultan F Power
Journal:  Vaccines (Basel)       Date:  2019-09-06

10.  Projecting influenza vaccine effectiveness: A simulation study.

Authors:  Thomas N Vilches; Affan Shoukat; Claudia Pio Ferreira; Seyed M Moghadas
Journal:  PLoS One       Date:  2020-11-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.